Oropharyngeal cancer, which can develop at the base of the tongue, tonsils, and the middle part of the throat, is primarily caused by human papillomavirus (HPV) infection, the most common sexually transmitted virus and infection in the United States.1
San Francisco, CA—The increasing rate of infection with the human papillomavirus (HPV) in the United States has changed the field of head and neck cancer, or oral cancer, and HPV infection now causes a growing majority (70%-90%) of oropharyngeal squamous-cell carcinomas. As its incidence is rising, so is patients’ curiosity about what sets this cancer apart from other malignancies.
Current National Comprehensive Cancer Network guidelines recommend initiating radiation therapy within 6 weeks of tumor resection, but the benefits of shorter time to radiation therapy, including locoregional control and survival, remain inconclusive.
Scottsdale, AZ—Therapeutic, low-level laser therapy (LLLT) reduces pain and accelerates the resolution of oral mucositis (OM) in patients with head and neck cancer receiving chemoradiotherapy (CRT), according to Eric Allan, MD.
North America is facing a shortage of certain drugs, and you do not have to be a pharmacist buyer tasked with procurement to realize our drug supply is under pressure. Governmental and professional groups—including the US Food and Drug Administration (FDA), American Society of Clinical Oncology (ASCO), Institute for Safe Medication Practices (ISMP), Association of Community Cancer Center, and American Pharmacists Associ ation, among others—have been stating that this is a serious problem that may not be resolved anytime soon.